Risk factors for the development of specific noncardiovascular adverse effects associated with XXXX .

@entity1 @entity2643 @entity3794 @entity272 @entity943
Noncardiovascular adverse effects associated with @entity2643 result in substantial morbidity. Adverse effects involving the skin, liver, thyroid, and lungs have been reported in as many as 57%, 55%, 11%, and 13% of @entity1 , respectively. Although risk factors for some @entity2643 -induced adverse effects have been identified, risk factors for these specific side effects have not been systematically evaluated. Therefore, risk factors for development of @entity2643 -induced dermatologic, hepatic, thyroid, or pulmonary adverse effects were identified using univariate analysis in 44 @entity1 receiving the drug for supraventricular or @entity943 (mean duration of therapy 99.5 +/- 110.8 weeks). Dermatologic side effects occurred in 4 (9.1%) @entity1 . @entity1 who experienced dermatologic side effects were younger than @entity1 who did not (mean age, 48.3 +/- 15.8 years versus 60.1 +/- 9.5 years, respectively; P = .03). @entity1 younger than 60 years of age were more likely to develop @entity272 than those aged 60 or older (P = .05). Hepatic adverse effects occurred in 3 (6.8%) @entity1 . Left ventricular ejection fraction was lower in those who developed hepatic adverse effects than in those who did not (15.0 +/- 4.0% versus 39.1 +/- 13.9%, P = .005). Adverse thyroid effects occurred in 6 (13.6%) @entity1 ; and @entity3794 occurred in 2 (4.5%) @entity1 . No specific risk factors for adverse thyroid effects or @entity3794 were revealed. In conclusion, age less than 60 may be a risk factor for @entity2643 -induced dermatologic adverse effects, whereas severely depressed left ventricular ejection fraction may be a risk factor for hepatic side effects associated with @entity2643 .
